1	Roche	NNP	2	nn
2	Holding	NNP	3	nn
3	AG	NNP	14	nsubj
4	,	,	3	punct
5	parent	NN	3	appos
6	of	IN	5	prep
7	the	DT	12	det
8	Swiss	JJ	12	amod
9	chemical	NN	12	amod
10	and	CC	9	cc
11	pharmaceutical	JJ	9	conj
12	group	NN	6	pobj
13	,	,	3	punct
14	said	VBD	0	root
15	its	PRP$	17	poss
16	group	NN	17	nn
17	sales	NNS	18	nsubj
18	rose	VBD	14	ccomp
19	22	CD	20	num
20	%	NN	18	dobj
21	in	IN	18	prep
22	the	DT	25	det
23	first	JJ	25	amod
24	nine	CD	25	num
25	months	NNS	21	pobj
26	of	IN	25	prep
27	the	DT	28	det
28	year	NN	26	pobj
29	to	TO	18	prep
30	7.32	CD	31	number
31	billion	CD	32	num
32	francs	NNS	29	pobj
33	-LRB-	-LRB-	34	punct
34	$	$	32	dep
35	4.51	CD	34	number
36	billion	CD	34	number
37	-RRB-	-RRB-	34	punct
38	.	.	14	punct

1	The	DT	2	det
2	company	NN	3	nsubj
3	reported	VBD	0	root
4	good	JJ	5	amod
5	gains	NNS	3	dobj
6	in	IN	5	prep
7	all	DT	6	pobj
8	of	IN	7	prep
9	its	PRP$	10	poss
10	divisions	NNS	8	pobj
11	.	.	3	punct

1	Roche	NNP	3	nsubj
2	also	RB	3	advmod
3	said	VBD	0	root
4	it	PRP	5	nsubj
5	expects	VBZ	3	ccomp
6	a	DT	9	det
7	``	``	9	punct
8	considerable	JJ	9	amod
9	rise	NN	5	dobj
10	''	''	9	punct
11	in	IN	9	prep
12	1989	CD	14	num
13	group	NN	14	nn
14	profit	NN	11	pobj
15	from	IN	9	prep
16	the	DT	24	det
17	641.5	CD	18	number
18	million-franc	JJ	24	amod
19	-LRB-	-LRB-	20	punct
20	$	$	24	dep
21	396	CD	20	number
22	million	CD	20	number
23	-RRB-	-RRB-	20	punct
24	net	NN	15	pobj
25	in	IN	24	prep
26	1988	CD	25	pobj
27	.	.	3	punct


